MedDataX Logo

Acromegaly - Before and After Treatment

NCT ID: NCT03431727

Last Updated: 2020-12-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-01

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acromegaly is a rare disease caused by a growth hormone (GH) producing pituitary adenoma. Surgery is primary treatment, whereas medical treatment with a somatostatin analogue (SA), which suppresses GH secretion and reduces tumour size, is used when surgery is insufficient or unfeasible. Acromegaly is associated with metabolic abnormalities which contributes to an increased morbidity and mortality if left untreated. To which extend these abnormalities reverses after treatment, and if treatment modality influences the outcome, remain elusive. The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acromegaly Growth Hormone Treatment Sleep Apnea Cardiovascular Diseases Bone Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Recently diagnosed with acromegaly
* Age above 18
* Written consent

Exclusion Criteria

\- Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jens Otto L Jørgensen, Porfessor

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital, Department of internal medicine and endocrinology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aarhus University Hospital, Department of internal medicine and endocrinologi

Aarhus, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mai C Arlien-Søborg, MD

Role: CONTACT

Phone: +45 23837420

Email: [email protected]

Jens Otto L Jørgensen, Professor

Role: CONTACT

Phone: +45 24800664

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mai C Arlien-Søborg, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1-10-72-126-16

Identifier Type: -

Identifier Source: org_study_id